Daily Archives: February 4, 2007

More Tools In Google’s Microsoft Assault

There has been a good deal of speculation that Google (GOOG) is in the process of building desktop software to compete with portions of Microsoft’s (MSFT) operating system functions. Google already has its own word processing and spreadsheet software that run on server-side, web-based platforms.

According to a report at TechCrunch, Google may be ready to add a "powerpoint-like" product as well.

While none of the Google products, even taken together, is a direct threat to Microsoft Vista or any of its key components, that could change if Google pulls together enough web-based products to replace most of those available from Redmond. It may not happen overnight, but, if it happens at all, Microsoft has a problem.

Douglas A. McIntyre can be reached at douglasamcintyre@247wallst.com. He does not own securities in companies that he writes about.

Best and Worst Performing Stocks Year to Date

From Ticker Sense

The tables below highlight the best and worst performing stocks in the Russell 3000 over the past 5 days, the past 3 months, and year to date.

1wk202

3mo202

Ytd202

http://www.tickersense.typepad.com/

Fourth Quarter Earnings Update

From Ticker Sense

At the end of last week, the percentage of S&P 500 companies beating earnings estimates stood at 69%.  After another week of numerous reports, the percentage now stands at 66%, indicating a less than stellar week on the earnings front.  The percentage of companies missing estimates is at 20%, the highest level since October 2005.

Earningsupdate202_1

Earningsmiss202_1

http://www.tickersense.typepad.com/

S&P 500 Trading Range

From Ticker Sense

While everyone has become so concerned about the market’s "frothiness" due to the lack of a 10% correction or even a 2% down day, we would highlight that the S&P 500 is currently trading less than 2.5% above its 50-day moving average.  On a historical basis, anything less than 5% above the 50-day moving average is considered neutral.  Based on this measure, the market has not been overbought at any point over the last two years, while it has been oversold once.

Sp_500_moving_average_envelope_1 

http://www.tickersense.typepad.com/

S&P/Case-Shiller Median Home Price Update with Futures

From Ticker Sense

The November S&P/Case-Shiller Home Price numbers were released this week, so we have updated our historical composite chart accordingly.  We also include the CME Futures prices that expire in February, May, August and November of this year to show where investors currently expect prices to be headed.

Caseshillercomp

Comptable_1

http://www.tickersense.typepad.com/

Overbought ETFs and Leveraged Sector ETFs

As shown, most areas of the US markets are currently overbought, with REIT ETFs being the most extended.  The DJIA tracking Diamonds (DIA) and the S&P 500 tracking SPDRs (SPY) are also above their normal trading ranges.  On a side note, The Kirk Report wrote an interesting piece on leveraged ETFs offered by ProShares that is worth a read.  ProShares now offers leveraged sector ETFs as well.  Unfortunately, these ETFs have not been around long enough to run our overbought/oversold on them, but once they have, we’ll be sure to include them.

Obets

Oboskey_29

http://www.tickersense.typepad.com/

Semiconductor Industry Should Quit Patting Itself on the Back (and Building Capacity)

By Wlliam Trent of Stock Market Beat

Semiconductor Industry Association provided the monthly global sales report for December.

The Semiconductor Industry Association (SIA) today reported that global sales of semiconductors reached a record $247.7 billion in 2006, an increase of 8.9 percent from the $227.5 billion reported in 2005. Worldwide sales in December were $21.7 billion, an increase of 9 percent from December 2005 when sales were $20 billion. December 2006 sales declined by 3.6 percent from the immediate-prior month, when sales were $22.5 billion. Worldwide sales in the fourth quarter were $65.2 billion, an increase of 9 percent over fourth-quarter 2005 sales of $59.9 billion and an increase of 1.9 percent over third-quarter 2006 sales of $64.0 billion….

[SIA President George] Scalise noted that 2006 global sales came within 0.4 percent of the SIA forecast of $248.8 billion. “With generally healthy economic conditions in all of the world’s major semiconductor markets, we believe our forecast of 10 percent growth to $273.8 billion in worldwide sales in 2007 is aligned,” Scalise concluded.

Lest you get the impression that the dudes at SIA are really on-the-ball forecasters, keep in mind that the 0.4 percent error was off of their most recent estimate. When the SIA issued their initial forecast for 2006 they said:

The forecast calls for 2005 sales to increase by 6.8 percent to $227.6 billion, followed by increases of 7.9 percent to $245.5 billion in 2006, 10.5 percent to $271.3 billion in 2007, and 13.9 percent to $309.2 billion in 2008.

Or perhaps we’re being more fair than we should. Given that they are forecasting several years ahead, their true initial forecast for 2006 occurred late in 2003, when they said:

Total Semiconductors: The total semiconductor market is expected to increase 15.8 percent to $163.0 billion in 2003. The SIA forecasts growth of 19.4 percent to $194.6 billion in 2004, 5.8 percent to $206.0 billion in 2005, and 6.6 percent to $219.6 billion in 2006.

Granted, the forecasts are about as good as anyone’s could be, and we wouldn’t disparage them in this way had Scalise not drawn attention to the excellence of their November forecast.

Now on to the real juice:

semisupply.jpg

The industry is still building too much capacity, and it got worse in December.

The author may hold a position in the securities discussed. The author’s current holdings are as follows: Long: Union Pacific (UNP) put options; Air Products (APD) put options; Nasdaq 100 (QQQQ) put options; Bookham (BKHM; Ballard Power (BLDP); Syntax Brillian (BRLC); CMGI (CMGI); Genentech (DNA); Ion Media Networks (ION); Three Five Systems (TFS); IShares Japan (EWJ); StreetTracks Gold (GLD); Starbucks (SBUX); U.S. Oil Fund (USO); Plantronics (PLT) call options; Short: Starbucks (SBUX) call options; Landstar (LSTR) put options; Plantronics (PLT) put options

http://stockmarketbeat.com/blog1/

Friday’s Top Biotech and Medical Stocks

From BioHealth Investor

Biotechnology

SEATTLE GENETICS I [SGEN] +11.38%
IMMUNOGEN INC [IMGN] +8.86%
IDM PHARMA INC [IDMI] +8.58%
SUNESIS PHARMACEUTIC [SNSS] +8.55%
SANGAMO BIOSCIENCE [SGMO] +8.52%

Diagnostic Substances

NYMOX PHARM CORP [NYMX] +44.72%
VALERA PHARMACEUTICA [VLRX] +6.03%
HEALTHCARE TECH LTD [HCTL] +5.33%
OSTEOLOGIX INC [OLGX.OB] +5.26%
ICAGEN, INC. [ICGN] +3.78%

Drug Delivery

QUIGLEY CORP THE [QGLY] +3.88%
DELCATH SYSTEMS INC [DCTH] +3.20%
ELAN CP PLC ADR [ELN] +2.35%
HOSPIRA INC [HSP] +0.71%
BIOVAIL CORP [BVF] +0.48%

Drug Manufacturers

ACCESS PHARMACEUTICL [ACCP.OB] +72.00%
ALLOS THERAPEUTICS [ALTH] +9.84%
ALEXZA PHARMACEUTICA [ALXA] +8.09%
MARSHALL EDWARDS [MSHL] +3.62%
PHARMAXIS LTD ADR [PXSL] +3.41%

Medical Appliances & Equipment

SPECTRASCIENCE NEW [SCIE.OB] +22.64%
INTUITIVE SURG INC [ISRG] +17.57%
TRIMEDYNE INC [TMED.OB] +8.55%
VOLCANO CORPORATION [VOLC] +8.05%
REGENERATION TECH [RTIX] +6.78%

Medical Instruments & Supplies

HEMOSENSE INC. [HEM] +12.58% $0
EV3 INC. [EVVV] +12.20% $0
ROCHESTER MEDICAL [ROCM] +11.45% $56.7 M
ATRICURE, INC. [ATRC] +11.45% $8.9 M
MILESTONE SCIENTIFIC [MLSS.OB] +7.89%

Medical Laboratories & Research

BIO-IMAGING TECH [BITI] +4.99%
MEDASORB TECHNOLOGS [MSBT.OB] +4.17%
ALLIANCE IMAGING INC [AIQ] +1.84%
ARRAY BIOPHARMA IN [ARRY] +1.02%
PHARM PROD DEV [PPDI] +0.98%

http://www.biohealthinvestor.com/

Access Pharmaceuticals Gains 70% on BusinessWeek Article

by H.S. Ayoub
BioHealth Investor.com

I first mentioned Access Pharmaceuticals (ACCP.OB) way back in October after the company’s shares doubled on 16x average volume with no news.

On Friday, shares of Access Pharmaceuticals jumped again, this time more than 70%, as a couple of fund managers declared in the upcoming February 12th issue of BusinessWeek magazine that the company’s stock is way undervalued.

In fact, one fund manager believes that the company’s flagship product, MuGard, which was approved in December of 2006 by the FDA, was alone worth more than the company’s market cap. MuGard is intended to be used by cancer patients suffering from oral mucositis as a side effect of chemotherapy. The company also has various other cancer drugs in late phase trials.

An analyst also suggested that the stock could be worth $10-$20 a share in two years! Of course, the fund manager is playing his prediction safe with such a wide range. It is like saying a stock could be worth anywhere between $50-$100.

Shares of ACCP where in the high $2 range before the article was released on the web on Friday morning, by the end of trading the stock is now over $5! A lot closer to that $10 eh!

I do have a problem with the latest price jump; how could a stock gain 70% on a mention? I am niave enough to believe that stocks are fairly hyped (notice I did not say fairly valued!), and a magazine article mentioning the opinions of fund managers who own the stock should not make that much of a difference.

Now granted, I am aware that shares of Access Pharmaceuticals trade on the bulletin board, with a market cap of less than $20 million, and a float of slightly more than 3 million shares. Regardless, a stock exchange is just like any other in that volatility is always inherent in a stock, but a 70% upside on an opinion is tremendous, even for a penny stock. This is especially so considering the 120% jump back in October that I previously wrote about.

I placed ACCP on my personal watch list back in October thinking that an FDA approval, which did happen in December, would be the real catalyst for a large jump. While shares of ACCP did gain in December following the FDA announcement, it was nothing compared to Friday’s.

Considering the trumultous history of ACCP’s stock, which after a failed nanotechnology venture went down from the $40 level all the way down to penny stock status, how could someone realistically consider it a good investment at this point?

I still do believe that Access Pharmaceuticals is a great little company, with great potential, but the company’s stock isway too wild for my blood, especially right now.

For those investors not shy of bungee jumping and skydiving, ACCP may prove to be a fun play. As for myself, I will gladly continue to just watch Access Pharmaceuticals from a safe distance, until a better opportunity presents itself.

http://www.biohealthinvestor.com/

IBD Weekly Top Ranked Medical Stocks

From BioHealth Investor

The following list represents the top ten medical stocks ranked according to Earnings Per Share and Relative Strength by Investor’s Business Daily (2/03/06)

scores out of 100 (last week’s rank, change in score):

1(1) Arrhythmia Research (HRT) EPS=96(+1) RS=99
2(2) Rochester Medical (ROCM) EPS=95 RS=99(+1)
3(3) Wellcare (WCG) EPS=96 RS=97(+1)
4(6) Mindray Medical (MR) EPS=99 RS=91(+2)
5(4) Immucor (BLUD) EPS=97(+1) RS=93(-2)
6(8) American Bio Eng (AOB) EPS=88(+1) RS=99
7(-) Emdeon (HLTH) EPS=98 RS=87
8(-) LHC Group (LHCG) EPS=98 RS=87
9(9) NightHawk Radiology (NHWK) EPS= 99 RS=86(+1)
10(-) West Pharma Srvcs (WST) EPS=94 RS=89

http://www.biohealthinvestor.com/

Biotech & Medical Venture Deals Roundup

by Adam Rubenstein

Claros Diagnostics (Woburn, MA) is developing a handheld disease monitoring device that allows anyone to perform laboratory-quality blood tests in any setting, has closed a $7.8M Series A financing. The round was led by Oxford Bioscience Partners along with, Accelerated Technologies Partners, and Commons Capital.

Ovalis (Mountain View, CA) a developer of catheter-based products for repairing cardiac defects, has raised around $6.6 million in Series B funding. Return backers include Abbott Labs, De Novo Ventures and Latterell Venture Partners.

Kolis Scientific (Morrisville, NC) is developing an outpatient-based treatment for a common ophthalmic condition, has closed a $15.1M Series A financing led by Quaker BioVentures, De Novo Ventures and Spray Venture Partners.

iBalance Medical (Boulder, CO) a developer of axial knee realignment systems, has expanded its Series A round to a total of $13.5M. Return backers include Sutter Hill Venture Partners and Skyline Ventures.

EyeGate Pharma (Waltham, MA) a pharmaceutical company pioneering the use of iontophoresis technology to deliver therapeutics for ocular indications, announced that it has closed on a $2M extension of its Series B, bringing the total of the financing to $12M. This funding comes from the Nexus Group, the round was originally led by Innoven Partenaires and Ventech.

Symphony Medical (Laguna Hills, CA) develops proprietary biopolymer and cellular-based biologic therapies to effectively treat chronic and post-operative atrial fibrillation and other cardiac conduction abnormalities, has raised $5M, bringing the aggregate investment in all rounds into Symphony Medical to $17 million. The only participants in the round were Domain Associates, Johnson & Johnson Development Corp., Morgenthaler Ventures and Triathlon Medical Ventures.

http://www.biohealthinvestor.com/

This Week on StockHouse January 29 to February 2

By the StockHouse editorial team

A fast-forward rewind of the week on StockHouse

StockHouse Executive Editor and Publisher Darin Diehl traded thoughts with Mad Money market maven Jim Cramer in an exclusive interview (http://www.stockhouse.ca/shfn/article.asp?edtID=19268 ) after the CNBC commentator appeared on a panel to help StockHouse launch its StockStream Platinum portfolio management tool to the U.S. market.

Micro-cap Monday columnist Danny Deadlock updated readers about the recent acquisition by biometric security company (http://www.stockhouse.ca/shfn/article.asp?edtID=19252 ) Bioscrypt (TSX: T.BYT), and showed how the purchase means Motorola (NYSE: MOT), Ellison and Logitech (NASDAQ: LOGI) are now Bioscrypt shareholders.

Investors in junior resource companies know that due diligence is crucial. Resourcex senior editor Doug Hadfield shed some light on how investors should read the National Instrument 43-101 Technical Report (http://www.stockhouse.ca/shfn/article.asp?edtID=19253).

Everyone who watches any of the shows that are part of the C.S.I. television franchise knows that tracking bad guys requires quick and easy genetic analysis (http://www.stockhouse.com/shfn/editorial.asp?edtID=19259 ). The Micro-cap Spotlight shone on eGene (OTC:BB: EGEI), a company that hopes to fill that niche and others.

Meanwhile, the Securities Sleuth dug up the data on a number of companies whose restatements (http://www.stockhouse.ca/shfn/article.asp?edtID=19263 ) have negatively impacted shareholders.

Just in time for the meeting of Federal Reserve policy makers, Steven Saville asked whether the current account deficit forecast (http://www.stockhouse.ca/shfn/article.asp?edtID=19264 ) a weaker U.S. dollar.

Weekly Wizard Jay Matulich said that he’s been buying bonds and gold (http://www.stockhouse.ca/shfn/article.asp?edtID=19265 ), because he says economic conditions are weaker than the market perceives.

While Don Vialoux pointed readers toward some U.S. energy sector ETFs (http://www.stockhouse.ca/shfn/article.asp?edtID=19272 ) that may see appreciation at this point.

A number of companies announced the spinning off of (http://www.stockhouse.ca/shfn/article.asp?edtID=19273 ) non-core assets in new initial public offerings. Jon Ogg at 24/7 Wall Street sorted out how the news was moving the parent firm’s stock.

Did you know you’re probably looking at Indium (http://www.stockhouse.ca/shfn/article.asp?edtID=19274 ) right now? Pure Metals columnist Luke Burgess showed how this element is precious, and how to invest in companies that produce it.

In the third installment of the Financially Fit series about investing in small-cap stocks (http://www.stockhouse.ca/shfn/article.asp?edtID=19277) Nancy Zambell presented a research primer for choosing the right funds and ETFs.

STANDUP Advice took another look at the active-passive dichotomy (http://www.stockhouse.ca/shfn/editorial.asp?edtID=19279 ).

Finally, for a list of the hot hits on StockHouse, the Top Five (http://www.stockhouse.ca/shfn/article.asp?edtID=19269 ) by Sean Mason and Keri Korteling gives the site lowdown in a list of lists.

GE To Replace NBC’s Wright After Mediocre Results

GE (GE) won’t sell its NBC Universal unit, so, after more disappointing quarterly numbers, it will put a new CEO in. Bob Wright, the head of the unit for years, will apparently be replaced by his No.2, Jeff Zucker. It is hard to say what GE gets out of the move.

Revenue at the NBC Universal unit grew 1% in the fourth quarter compared to a year ago. Segment profit rose 5% to $841 million. With GE’s total revenue up 11% and segment profit up 13%, the entertainment unit was not exactly a standout.

NBC Universal has said that it will need to increase its digital and internet revenue to improve its results. Although the GE unit has already begun making content available in new venues, all other major studios and television networks are doing the same. And, user-created video content is clearly competing for user time online.

Even with a new CEO in place, the chorus on Wall St. will keep calling for the unit to sold. Perhaps it can be packaged with the plastics unit and spun off to shareholders. Right.

Douglas A. McIntyre can be reached at douglasamcintyre@247wallst.com. He does not own securities in companies that he writes about.

Memo To Dell (DELL) Workers: So Much For Bonuses

Michael Dell, one of the world’s richest men, decided to cut bonuses for most of the people at the PC firm who would have been candidates to get them for 2006. Many will get better raises for the upcoming year.

What a foolish move.

For starters, most of the people who will not get bonuses could hardly be held responsible for the company’s poor performance in 2006. That distinction would be at the feet of Mr. Dell himself, his hand-picked CEO Kevin Rollin, and a handful of other senior managers. To a large extent, by defending Rollins and keeping him in his job too long (Investors should assume that Mr. Rolling will get his bonus for 2006 and much more in his severance),  Michael Dell did nothing to help the firm he started while it lost share to companies like Hewlett-Packard (HPQ).

The memo is filled with other silly comments like "We will have clear priorities and a focused strategy". As Chairman and the company’s founder, Wall St. has to wonder how he let that critical part of corporate management go off track for so long.

So, we have Michel Dell, who in fiscal 2006 made a base salary of $950,000 and a bonus of $1.8 million, telling his employees that they will get no bonuses. This is the same Michael Dell who owned over 216 million Dell shares as of the last company proxy.

Please, please make my shares worth more. Take no bonus. But trust me. I’ll make it up to you later.

Douglas A. McIntyre can be reached at douglasamcintyre@247wallst.com. He does not own securities in companies that he writes about.

HFF Holdings IPO

Our pre-ipo piece on HF. As always, we put together in depth analysis pieces on every ipo well before they price/open….including all four of todays ipos HF/AHII/EIG/DEP.

http://www.tradingipos.com

Disclosure: at time of this blog post tradingipos.com does have a position in HF at 18.20

2007-01-22
HF – HFF Holdings

HF – HFF Holdings plans on offering 16.5 million shares(assuming over-allotment) at a range of $15-$17. Goldman Sachs and Morgan Stanley are lead managing with BofA, Wachovia, JP Morgan and Lehman co-managing. Post-offering HF will have 39 million shares outstanding for a market cap of $624 million on a $16 pricing. Approximately 3/4 of the ipo proceeds will go to pay partnership holders as HF converts from a partnership to a publicly traded company. 1/4 of the ipo proceeds will go to repay debt.

As HF was structured as a partnership prior to ipo, management, board and employees will own essentially all outstanding shares not sold on ipo. Assuming over-allotment is exercised that equals 55%-60% of ownership in HF. Note that these shares will still be listed as partnership units post-ipo, much as the Evercore IPO was structured.

From the prospectus:

‘We are a leading provider of commercial real estate and capital markets services to the U.S. commercial real estate industry based on transaction volume and are one of the largest private full-service commercial real estate financial intermediaries in the country.’

HF is an expertise operation. Expertise ipos rely heavily on their employees/management, one reason why HF was structured as a partnership pre-ipo. Expertise ipos tend to do rather well overall. We’ve seen a number of successful ‘expertise’ ipos the past few years including GFIG/EVR/GHL/LAZ and HF’s direct comparable CBG. Note that CBG is up approximately 500% since the 2004 ipo, reason enough to take this HF offering seriously.

HF operates out of 18 offices in the US staffed by 130 transaction professionals. In 2005, HF advised clients in transactions covering 44 states and 500 cities. Revenues are derived from client fees on a transaction by transaction basis.

HF operates as ‘one stop shop’ for commercial real estate including debt placement, investment sales, structured finance, investment banking/advisory, private equity, note sales and commercial loan servicing.

Note what HF does not do: They are not involved in leasing or property management nor does HF engage in principal commercial property investing. HF feels this allows them to provide objective advice to clients and to act as impartial broker to both sides of their deals.

A quick look at HF’s services:

Debt placement – Construction loans, adjustable and fixed rate mortgages, entity level debt, mezzanine debt, forward delivery loans, tax exempt financing, andsale/leaseback financing. Clients are owners of various types of property, including, office, retail, industrial, hotel, multi-family etc… Debt is placed with every imaginable possible debt placement client including life insurance companies, investment banks, commercial banks, thrifts, agency lenders, pension funds etc…. Keep in mind HF is transacting and placing the debt, not carrying the mortgages on their own books. HF makes money from the deal flow, not the appreciation or depreciation of the assets in the future. In 2005 HF’s value in debt placements was approximately $22 billion, an approximately 11% share of the entire US commercial debt placement market.

Investment Sales – HF provides investment sales services to commercial real estate owners who are seeking to sell one or more properties. Essentially HF acts as a commercial real estate agent. In 2005 HF was the agent for $7.6 billion in investment sales, which was approximately a 3% US market share.

Structured Finance – Alternative investment expertise in mezzanine, preferred equity, participating and/or convertible debt structures, bridge loans. HF will participate in structuring these alternative financing options to fit the clients needs. In 2005 HF acted as broker/dealer in approximately $2.1 billion of structured finance

Private equity, Investment banking, and Advisory services – HF serves as a real estate investment banker/adviser for clients desiring to access the private equity investment market as well as advising clients in financial transactions. Services include commercial real estate investment banking/advising services for direct private equity investments, joint ventures, private placements, management buyouts,and mergers and acquisitions(M&A). HF really just kicked off their real estate investment banking/advisory services in 2005. HS was involved in $100 million in total transactions in this niche in 2005 and over $1 billion through the first 9 months of 2006. It appears this niche will be a prime growth driver for HF going forward as they grab commercial real estate M&A market share.

Typical clients for HF’s services include both users of capital, such as property owners, and providers of capital, such as lenders and equity investors.Clients will often act as both users and providers of capital in different transactions. Over the past three years no single client represented more then 4% of overall revenues.

Growth plan – Expand geographic penetration, increase market share and capitalize on cross-selling opportunities. HF’s growth focus will be to locate and bring on board commercial real estate transaction professionals in smaller US market not currently covered by HF. Also note that HF has quickly grown their commercial real estate M&A arm in 2006, from essentially start-up stage in 2005.

Risks – HF is heavily leveraged to overall commercial real estate activities. To make money, HF needs to see sustained interest in commercial real estate transactions. As HF notes in the prospectus, ‘Historically, commercial real estate markets, and in particular the U.S. commercial real estate market, have tended to be cyclical and related to the condition of the economy as a whole and to the perceptions of the market participants as to the relevant economic outlook.’ Overall the commercial real estate market has been in a cyclical upswing for most of the US after a 2002/2203 trough.

Financials

no substantial cash or debt on the books post-offering.

No dividends planned.

Revenues – HF has grown revenues annually throughout the decade, with strong growth of 40%-55% coming in 2004-2005. For full year 2005, HF booked revenues of $206 million. As with most expertise companies, compensation to producing partners is the greatest expense line. HF’s transaction professional are primarily paid in commissions, salary and bonus. The direct expense line for all employee compensation appears to be approximately 65% of revenues the past 18 months. Expect this % to remain fairly robust as is common with this type of operation.

In 2005 HF had operating margins of 23%, fully taxed net margins of 16% and earnings per share of $0.82.

2006 – Through the first 9 months of 2006, HF appears as if they will grow revenues 15% for the full year to $235-$240 million. Operating and net margins will be in the same ballpark as 2005. Full year 2006, HF should earn approximately $1 per share. On a $16 pricing, HF would be trading 16 X’s 2006 earnings.

2007 – As long as the commercial real estate market remains active, HF is positioned to have a very good year. With their burgeoning private equity placement and M&A arm to go with their strong debt placement and commercial agent segments, another 10%-20% revenue growth year should be achievable. The largest expense item, employee compensation, does not look to drop as a % of revenues so there will not be a significant margin increase as revenues increase. At a 15% 2007 revenue increase that would mirror 2006’s % increase, HFF should earn $1.15-$1.20. This number is a ballpark number only at this point and could change each way depending on HF’s success in garnering a larger slice of the pie and general commercial real estate activity. I would surmise that the earnings per share would not be a whole lot lower then this forecast unless the US economy ran into a recessionary climate the back half of 2007. At those estimate, HFF would be trading 13-14 X’s 2007 earnings on a $16 pricing.

Concern – I would prefer to see a smaller employee related expense % here. 65% total appears rather steep and it doesn’t appear as if HF has any plans on lowering that number going forward. Many of the broker/dealer and investment banking ipos we’ve seen the past 3-4 years have committed to capping employee compensation going forward at 55%-60%. HF’s 65% is a bit above there.

CBG is HF’s closest publicly traded comparable. Keep in mind that CBG is a behemoth in the sector, much larger, more diverse and covers a larger geographic area then HF. A quick glance at each:

CBG, $8 billion market cap. Currently trades 24 X’s 2006 earnings and 19 X’s 2007 estimates with a projected 25% 2007 revenue growth, fueled in part from acquisitions.

HF, $624 million market cap on a $16 pricing. At $16 would trade 16 X’s 2006 earnings and 13-14 X’s conservative 2007 estimate with a projected revenue growth in 2007 of approximately 15%.

CBG is up 500% since ipo late in 2004. If the commercial real estate market just remains stable, HF is a solid ipo coming at a very reasonable multiple. Really I would only be concerned in pricing range if the US economy slows in a recession like climate. Otherwise the multiple is reasonable enough in range that HF should do quite well. Whenever an ipo’s closest comparable is up 500% from offer, you’ve got to take notice. Factor in also that ‘expertise’ ipos have as a rule done very well this decade and HF should work quite well. I like this deal quite a bit.

HF is not a direct play on the valuation and strength of the real estate market. They’re a play on the transaction growth this decade of structured finance and debt placement in the commercial real estate market. In a fashion this is similar to the growth of derivatives and the resultant effect on the broker/dealer and exchange sector. For HF, the underlying price does not matter so much as long as there is sustained demand for transactions, refinancings, alternative debt structuring, debt placement etc…This is a big reason that CBG’s chart looks a lot like those of the derivatives exchanges and derivatives broker/dealer GFIG since ipo. They’ve all benefited from the heavy growth in transaction flow in their markets, not the overall valuation of the underlying assets. This is a key difference to a business linked directly to the underlying prices involved in said transactions.

Yes a sustained downturn in the commercial real estate market would have an impact on these activities. However it would most likely take a pretty severe overall economic downturn to curtail HF’s core revenue streams. HF stands to do well as long as commercial real estate transaction activity overall remains fairly strong, regardless of the underlying pricing fluctuations. In very simple terms, if the US economy avoids recession, HF should do quite well.